inovio.comINOVIO Pharmaceuticals

For Patients: Clinical Trials Publications Careers Contact Us Toggle navigation About INOVIO Purpose, Mission and Values Leadership Partnerships DNA Medicines Technology Optimized Plasmid Design and Delivery DNA Medicines Explained The Promise of DNA Medicine NEXT GEN DNA MEDICINE DNA Medicines Pipeline Investors & Media Events & Presentations Stock Information News Releases SEC Filings Analyst Coverage Corporate Governance Shareholder Services FAQ For Patients: Clinical Trials Publications Careers Contact Us About INOVIO Purpose, Mission and Values Leadership Partnerships DNA Medicines Technology Optimized Plasmid Design and Delivery DNA Medicines Explained The Promise of DNA Medicine NEXT GEN DNA MEDICINE DNA Medicines Pipeline Investors & Media Events & Presentations Stock Information News Releases SEC Filings Analyst Coverage Corporate Governance Shareholder Services FAQ For Patients: Clinical Trials Publications Careers Contact Us WORKING TO CHANGE TREATMENT PARADIGMS AND IMPROVE LIVES We’re developing innovative, next-generation medicines to fight HPV-related diseases, cancer and infectious diseases. LEARN MORE DRIVING PROGRESS WITH CUTTING-EDGE TECHNOLOGY Our platform features optimized design and delivery of medicines that teach the body to manufacture its own disease-fighting tools. LEARN MORE BUILDING ON THE PROMISE OF DNA MEDICINE A growing body of research indicates that DNA medicines offer many potential advantages and are generally well-tolerated, versatile, immunogenic and scalable. LEARN MORE HARNESSING THE POWER OF IN VIVO PROTEIN PRODUCTION INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. We use proprietary technology to design DNA plasmids —small circular DNA molecules that work like software that the body’s cells can download to learn how to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA® delivery devices help ensure our DNA medicines enter the body’s cells for optimal effect. Latest Inovio News May 13, 2024 INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights (read more) April 29, 2024 INOVIO to Participate in Upcoming Investor Conferences in May (read more) April 29, 2024 INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 (read more) LAURENT HUMEAU, Ph.D. Chief Scientific Officer Our research is advancing the next generation of DNA medicine technology and driving innovation in how we treat and protect people from disease.” Learn More MARK TWYMAN, MBA Chief Commercial Officer Our goal is to redefine success in the treatment of HPV-related diseases, cancer and beyond, for patients across the globe. DNA medicine offers ground-breaking potential advantages.” Learn More STEPHEN KEMMERRER Senior Vice President, Engineering Development Our cutting-edge delivery technology helps our DNA medicines get where they need to be for optimal impact – inside the cell, providing instructions to fight disease.” Learn More JACQUELINE SHEA, Ph.D. PRESIDENT & CHIEF EXECUTIVE OFFICER "INOVIO is committed to developing innovative new medicines for patients. We are building a uniquely experienced team, with a focus on scientific and operational excellence, to bring our DNA medicine candidates to market to benefit patients." Learn More PETER KIES CHIEF FINANCIAL OFFICER DNA medicine has the potential to be transformational for patients around the world. We are dedicated to delivering on that promise.” Learn More MICHAEL SUMNER Chief Medical Officer Across our pipeline we’re working to advance DNA medicine and develop innovative, next-generation therapies with groundbreaking potential.” Learn More SUBSCRIBE FOR UPDATES FROM INOVIO Register to receive email alerts for INOVIO press releases About Inovio DNA Medicines Technology DNA Medicines Pipeline Investors & Media For Patients Publications Careers Contact Us Safe Harbor Statement Expanded Access Privacy Policy Terms & Conditions © Copyright 2024 . All rights...